Literature DB >> 18385424

Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease.

Giovanni Targher1, Michel Chonchol, Lorenzo Bertolini, Stefano Rodella, Luciano Zenari, Giuseppe Lippi, Massimo Franchini, Giacomo Zoppini, Michele Muggeo.   

Abstract

It is unknown whether chronic kidney disease (CKD) is associated with nonalcoholic fatty liver disease among patients with type 2 diabetes. We followed 1760 outpatients with type 2 diabetes and normal or near-normal kidney function and without overt proteinuria for 6.5 yr for the occurrence of CKD (defined as overt proteinuria and/or estimated GFR <60 ml/min per 1.73 m(2)). During follow-up, 547 participants developed incident CKD. Nonalcoholic fatty liver disease, diagnosed by liver ultrasound and exclusion of other common causes of chronic liver disease, was associated with a moderately increased risk for CKD (hazard ratio 1.69; 95% confidence interval 1.3 to 2.6; P < 0.001). Adjustments for gender, age, body mass index, waist circumference, BP, smoking, diabetes duration, glycosylated hemoglobin, lipids, baseline estimated GFR, microalbuminuria, and medications (hypoglycemic, lipid-lowering, antihypertensive, or antiplatelet drugs) did not appreciably attenuate this association (hazard ratio 1.49; 95% confidence interval 1.1 to 2.2; P < 0.01). In conclusion, our findings suggest that nonalcoholic fatty liver disease is associated with an increased incidence of CKD in individuals with type 2 diabetes, independent of numerous baseline confounding factors.

Entities:  

Mesh:

Year:  2008        PMID: 18385424      PMCID: PMC2488256          DOI: 10.1681/ASN.2007101155

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  46 in total

1.  Diabetic nephropathy: prevention and treatment.

Authors:  H H Parving
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

2.  Nephropathy in diabetes.

Authors:  Mark E Molitch; Ralph A DeFronzo; Marion J Franz; William F Keane; Carl Erik Mogensen; Hans-Henrik Parving; Michael W Steffes
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

Review 3.  Diabetic renal disease: from recent studies to improved clinical practice.

Authors:  C E Mogensen; M E Cooper
Journal:  Diabet Med       Date:  2004-01       Impact factor: 4.359

4.  Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.

Authors:  Brent A Neuschwander-Tetri; Elizabeth M Brunt; Kent R Wehmeier; Dana Oliver; Bruce R Bacon
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

5.  Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study.

Authors:  Graziella Bruno; Franco Merletti; Annibale Biggeri; Giuseppe Bargero; Stefania Ferrero; Gianfranco Pagano; Paolo Cavallo Perin
Journal:  Diabetes Care       Date:  2003-07       Impact factor: 19.112

6.  National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors:  Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

7.  Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.

Authors:  Marie-Christine Alessi; Delphine Bastelica; Alenka Mavri; Pierre Morange; Bruno Berthet; Michel Grino; Irene Juhan-Vague
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-15       Impact factor: 8.311

8.  Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.

Authors:  John B Dixon; Prithi S Bhathal; Norman R Hughes; Paul E O'Brien
Journal:  Hepatology       Date:  2004-06       Impact factor: 17.425

Review 9.  AGE, RAGE, and ROS in diabetic nephropathy.

Authors:  Adeline L Y Tan; Josephine M Forbes; Mark E Cooper
Journal:  Semin Nephrol       Date:  2007-03       Impact factor: 5.299

10.  The utility of radiological imaging in nonalcoholic fatty liver disease.

Authors:  Sherif Saadeh; Zobair M Younossi; Erick M Remer; Terry Gramlich; Janus P Ong; Maja Hurley; Kevin D Mullen; James N Cooper; Michael J Sheridan
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682

View more
  60 in total

1.  Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.

Authors:  Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Giuseppe Lippi; Giacomo Zoppini; Michel Chonchol
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-19       Impact factor: 8.237

2.  The relationship between epicardial adipose tissue and malnutrition, inflammation, atherosclerosis/calcification syndrome in ESRD patients.

Authors:  Kultigin Turkmen; Hatice Kayikcioglu; Orhan Ozbek; Yalcin Solak; Mehmet Kayrak; Cigdem Samur; Melih Anil; Halil Zeki Tonbul
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-14       Impact factor: 8.237

Review 3.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

4.  Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth.

Authors:  Clara E Dismuke-Greer; Wing-Kin Syn
Journal:  Dig Dis Sci       Date:  2019-03       Impact factor: 3.199

5.  Liver stiffness assessed by transient elastography as a potential indicator of chronic kidney disease in patients with nonalcoholic fatty liver disease.

Authors:  Shaoyou Qin; Song Wang; Xu Wang; Jiangbin Wang
Journal:  J Clin Lab Anal       Date:  2018-09-21       Impact factor: 2.352

6.  Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients.

Authors:  G Targher; L Bertolini; M Chonchol; S Rodella; G Zoppini; G Lippi; L Zenari; E Bonora
Journal:  Diabetologia       Date:  2010-04-06       Impact factor: 10.122

Review 7.  Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.

Authors:  Mehmet Kanbay; Mustafa C Bulbul; Sidar Copur; Baris Afsar; Alan A Sag; Dimitrie Siriopol; Masanari Kuwabara; Silvia Badarau; Adrian Covic; Alberto Ortiz
Journal:  J Nephrol       Date:  2020-05-21       Impact factor: 3.902

8.  Serum gamma-glutamyltransferase levels are inversely related to endothelial function in chronic kidney disease.

Authors:  Mahmut Ilker Yilmaz; Faruk Turgut; Mehmet Kanbay; Mutlu Saglam; Alper Sonmez; Halil Yaman; Seref Demirbas; Hilmi Umut Unal; Mahmut Gok; Murat Karaman; Seyit Ahmet Ay; Erkan Demirkaya; Adrian Covic; Juan Jesus Carrero
Journal:  Int Urol Nephrol       Date:  2012-12-15       Impact factor: 2.370

9.  Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes.

Authors:  Yongqiang Li; Shuangshuang Zhu; Bin Li; Xiaofei Shao; Xinyu Liu; Aiqun Liu; Bifang Wu; Ying Zhang; Honglei Wang; Xiaohong Wang; Kangping Deng; Qin Liu; Min Huang; Hongmei Liu; Harry Holthöfer; Hequn Zou
Journal:  Int Urol Nephrol       Date:  2014-08-07       Impact factor: 2.370

10.  Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events.

Authors:  Hamdy Abd El Azeem; El-Shazly Abdul Khalek; Hazem El-Akabawy; Hussein Naeim; Hammouda Abdul Khalik; Abdul Aziz Alfifi
Journal:  J Saudi Heart Assoc       Date:  2013-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.